Cellectar Biosciences (CLRB) Competitors $0.24 0.00 (-1.26%) (As of 12/20/2024 05:45 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrends CLRB vs. ACHL, CLNN, DTIL, LEXX, VYNE, ATNM, OCX, LTRN, ELEV, and LUMOShould you be buying Cellectar Biosciences stock or one of its competitors? The main competitors of Cellectar Biosciences include Achilles Therapeutics (ACHL), Clene (CLNN), Precision BioSciences (DTIL), Lexaria Bioscience (LEXX), VYNE Therapeutics (VYNE), Actinium Pharmaceuticals (ATNM), OncoCyte (OCX), Lantern Pharma (LTRN), Elevation Oncology (ELEV), and Lumos Pharma (LUMO). These companies are all part of the "pharmaceutical products" industry. Cellectar Biosciences vs. Achilles Therapeutics Clene Precision BioSciences Lexaria Bioscience VYNE Therapeutics Actinium Pharmaceuticals OncoCyte Lantern Pharma Elevation Oncology Lumos Pharma Achilles Therapeutics (NASDAQ:ACHL) and Cellectar Biosciences (NASDAQ:CLRB) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, valuation, dividends, analyst recommendations, earnings, profitability, community ranking and risk. Does the media favor ACHL or CLRB? In the previous week, Cellectar Biosciences had 5 more articles in the media than Achilles Therapeutics. MarketBeat recorded 5 mentions for Cellectar Biosciences and 0 mentions for Achilles Therapeutics. Cellectar Biosciences' average media sentiment score of 0.60 beat Achilles Therapeutics' score of 0.00 indicating that Cellectar Biosciences is being referred to more favorably in the news media. Company Overall Sentiment Achilles Therapeutics Neutral Cellectar Biosciences Positive Which has more risk & volatility, ACHL or CLRB? Achilles Therapeutics has a beta of 1.37, indicating that its stock price is 37% more volatile than the S&P 500. Comparatively, Cellectar Biosciences has a beta of 0.89, indicating that its stock price is 11% less volatile than the S&P 500. Do institutionals and insiders hold more shares of ACHL or CLRB? 56.4% of Achilles Therapeutics shares are held by institutional investors. Comparatively, 16.4% of Cellectar Biosciences shares are held by institutional investors. 5.4% of Achilles Therapeutics shares are held by insiders. Comparatively, 3.7% of Cellectar Biosciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. Does the MarketBeat Community favor ACHL or CLRB? Cellectar Biosciences received 226 more outperform votes than Achilles Therapeutics when rated by MarketBeat users. Likewise, 55.86% of users gave Cellectar Biosciences an outperform vote while only 54.84% of users gave Achilles Therapeutics an outperform vote. CompanyUnderperformOutperformAchilles TherapeuticsOutperform Votes1754.84% Underperform Votes1445.16% Cellectar BiosciencesOutperform Votes24355.86% Underperform Votes19244.14% Which has stronger valuation & earnings, ACHL or CLRB? Achilles Therapeutics is trading at a lower price-to-earnings ratio than Cellectar Biosciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAchilles TherapeuticsN/AN/A-$69.67M-$1.65-0.59Cellectar BiosciencesN/AN/A-$42.77M-$1.72-0.14 Is ACHL or CLRB more profitable? Cellectar Biosciences' return on equity of 0.00% beat Achilles Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Achilles TherapeuticsN/A -54.45% -47.68% Cellectar Biosciences N/A N/A -191.22% Do analysts recommend ACHL or CLRB? Achilles Therapeutics presently has a consensus price target of $4.00, suggesting a potential upside of 308.16%. Cellectar Biosciences has a consensus price target of $17.67, suggesting a potential upside of 7,417.73%. Given Cellectar Biosciences' stronger consensus rating and higher possible upside, analysts plainly believe Cellectar Biosciences is more favorable than Achilles Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Achilles Therapeutics 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50Cellectar Biosciences 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.67 SummaryCellectar Biosciences beats Achilles Therapeutics on 10 of the 15 factors compared between the two stocks. Ad Insiders ExposedHas Trump Finally Gone Too Far?Lately, there's been a lot of buzz around a secret loophole executive insiders are using to make millions buying and selling their own stocks. It's so powerful ... so profitable ... that most people immediately assume this is just another example of Trump doing what's best for business executives. But surprisingly, this loophole has been on the books for many years and executives have been using it to make HUNDREDS of millions of dollars. And here's the good news.Register For The Webinar To Discover Get Cellectar Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for CLRB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CLRB vs. The Competition Export to ExcelMetricCellectar BiosciencesPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$9.70M$6.57B$5.13B$9.07BDividend YieldN/A2.99%5.08%4.23%P/E Ratio-0.1410.4289.5817.17Price / SalesN/A195.801,116.12116.95Price / CashN/A57.1642.8237.86Price / Book-0.245.094.774.78Net Income-$42.77M$151.83M$120.15M$225.60M7 Day Performance-9.62%-2.13%-1.92%-1.23%1 Month Performance-85.13%-3.10%11.47%3.36%1 Year Performance-91.10%11.54%30.54%16.60% Cellectar Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CLRBCellectar Biosciences1.8001 of 5 stars$0.24-1.3%$17.67+7,417.7%-90.9%$9.70MN/A-0.1410Analyst ForecastGap UpACHLAchilles Therapeutics2.9925 of 5 stars$0.99-0.2%$4.00+304.9%+18.1%$40.60MN/A-0.60250CLNNClene3.7369 of 5 stars$4.75-4.0%$55.25+1,063.2%-57.3%$39.71M$650,000.00-0.94100Analyst ForecastNews CoverageDTILPrecision BioSciences4.4752 of 5 stars$5.08-6.6%$39.50+677.6%-56.3%$38.97M$75.10M90.67200Gap DownLEXXLexaria Bioscience3.1515 of 5 stars$2.22-0.9%$11.00+395.5%+71.5%$38.75M$464,278.00-4.777VYNEVYNE Therapeutics2.6641 of 5 stars$2.60+1.6%$6.88+164.4%-3.8%$38.35M$493,000.00-2.9830News CoverageATNMActinium Pharmaceuticals1.252 of 5 stars$1.22-0.8%$7.40+506.4%N/A$38.07M$81,000.00-0.8849OCXOncoCyte3.2625 of 5 stars$2.26-2.6%$4.42+95.4%-22.1%$38.04M$1.50M0.00120Analyst ForecastGap DownLTRNLantern PharmaN/A$3.52+2.0%N/A-19.1%$37.96MN/A-1.9420Gap DownELEVElevation Oncology1.988 of 5 stars$0.64+0.8%$7.20+1,023.2%+26.0%$37.90MN/A-0.7840Analyst ForecastLUMOLumos Pharma3.1 of 5 stars$4.34flat$8.63+98.7%+44.2%$37.54M$2.21M-1.0130High Trading Volume Related Companies and Tools Related Companies ACHL Alternatives CLNN Alternatives DTIL Alternatives LEXX Alternatives VYNE Alternatives ATNM Alternatives OCX Alternatives LTRN Alternatives ELEV Alternatives LUMO Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:CLRB) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredTop Picks for Trump’s Pro-Crypto AmericaCoins Set to Soar with a Pro-Crypto White House President-Elect Donald Trump is reported to be holding over...Crypto 101 Media | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cellectar Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cellectar Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CLRB Stock Alerts